Related by context. All words. (Click for frequent words.) 87 Randomized Phase 87 Initiate Phase 85 Pivotal Phase III 85 Meets Primary Endpoint 85 Phase 2b Clinical Trial 82 Phase IIb Trial 82 Completes Patient Enrollment 82 Initiates Phase 82 Phase III Clinical Trial 81 Initiated Phase 80 Phase III Pivotal 80 Trial Evaluating 80 Completes Enrollment 80 Confirmatory Phase 80 Patient Enrollment 80 Pooled Analysis 80 Successfully Completes Phase 80 Pivotal Trial 79 Pivotal Study 79 Phase III Trial 79 Phase 2a Clinical Trial 79 Commences Phase 79 Second Pivotal Phase 79 Study Evaluating 79 Phase IIb Clinical Trial 79 Phase 2b Trial 79 Oral Fingolimod 79 Phase 1b Clinical Trial 79 Clinical Trial Results 79 Hormone Refractory Prostate Cancer 78 Initiates Phase II 78 Randomized Phase II 78 Combination REOLYSIN R 78 Novel Oral 78 Metastatic Melanoma 78 Adjuvant Treatment 77 Pivotal Trials 77 Drug Candidate 77 Initiate Phase III 77 Phase III Clinical Trials 77 Lung Cancer Trial 77 Randomized Double Blind 77 Presents Positive 77 Oral Calcitonin 77 Initiates Phase III 77 Phase 2a Trial 77 Commence Phase 77 Phase 2b Study 76 JAK Inhibitor 76 Advanced Melanoma 76 Dose Ranging 76 Patients Treated With 76 Dose Escalation 76 Receives Orphan Drug Designation 76 Clinical Trial Evaluating 76 Investigational Compound 76 Metastatic Colorectal Cancer 76 First Patient Enrolled 76 Phase IIa Clinical Trial 76 NDA Submission 76 First Patient Dosed 76 Phase III Trials 76 Brentuximab Vedotin SGN 75 Prolongs Survival 75 Monotherapy 75 Severe Sepsis 75 Relapsed Multiple Myeloma 75 Aflibercept 75 Topline Results 75 Dose Ranging Study 75 Demonstrates Positive 75 Initiates Clinical Trial 75 Antitumor Activity 75 Preclinical Data 75 Achieves Primary Endpoint 75 FDA Accepts 75 Combination Treatment 75 Improves Survival 75 Study Showed 75 Initiates Enrollment 75 Single Dose 75 Demonstrates Significant 75 Files IND 74 Demonstrates Potent 74 II Clinical Trial 74 Pharmacokinetic Study 74 Previously Treated 74 Prospective Randomized 74 Initiates Clinical 74 Mylan Receives Approval 74 Investigational Drug 74 Controlled Trial 74 Efficacy Trial 74 Treatment Naive Patients 74 dependent kinase inhibitor 74 SPRYCEL ® 74 Protease Inhibitor 74 Lung Cancer Drug 74 Tezampanel 74 Patients Treated 74 Plus Ribavirin 74 Presents Preclinical Data 74 PRN FDA Approves 74 AZX# Phase 74 Complicated Skin 74 Elagolix 74 Initiates Phase 2b 74 Double Blind Placebo 74 mGluR5 negative 74 Improves Outcomes 74 Chronic Hepatitis C 74 Anti Tumor Activity 73 Spectrum Pharmaceuticals Announces 73 placebo controlled Phase 73 IND Application 73 Treatment Naïve 73 Randomized Clinical Trial 73 Pivotal Phase II 73 Multicenter Randomized 73 Advanced Prostate Cancer 73 Demonstrated Significant 73 Is Well Tolerated 73 Randomized Double blind 73 Renal Cell Carcinoma 73 Begins Dosing 73 Collaborators Present 73 Relapsing Multiple Sclerosis 73 Long Term Efficacy 73 Patients Enrolled 73 Hsp# Inhibitor 73 Investigational Treatment 73 Patients Receiving 73 Survival Benefit 73 Newly Diagnosed Multiple Myeloma 73 Testosterone MDTS ® 73 Submits NDA 73 Well Tolerated 73 Parathyroid Hormone 73 FOLOTYN ® 73 Drug Fails 73 Sapacitabine 73 Resistant Hypertension 73 novel VDA molecule 73 Dose Finding 73 Phase III Pivotal Trial 73 Insulin Glargine 73 Desvenlafaxine Succinate 73 Lupus Nephritis 73 Gout Drug 73 Investigational Agent 73 Pivotal Clinical Trial 73 HDAC Inhibitor 73 MKC# MT 73 Granted Orphan Drug 72 Metastatic Prostate Cancer 72 Fast Track Status 72 Lupus Drug 72 Safinamide 72 Presents Preclinical 72 Diabetic Nephropathy 72 evaluating mipomersen 72 Metastatic Renal Cell Carcinoma 72 Initiate Clinical Trial 72 Vicriviroc 72 Personalized Immunotherapy 72 Statistically Significant 72 Peginterferon Alfa 2a 72 Refractory Hodgkin Lymphoma 72 Generic Version 72 Ozarelix 72 IND Filing 72 FDA Approvals 72 HCV SPRINT 72 Blood Pressure Drug 72 Subgroup Analysis 72 Recombinant Human 72 Mg Usa 72 Anti Tumor 72 BRIM2 72 Shows Promising 72 Shows Efficacy 72 Ranolazine 72 Cutaneous T 72 Improved Survival 72 Anticancer Activity 72 Investigational Oral 72 Peginterferon 72 Pulmonary Arterial Hypertension 72 Earns Milestone Payment 72 Present Preclinical Data 72 oral prodrug 72 Benign Prostatic Hyperplasia 72 Medoxomil 72 Aurora Kinase 72 Hypertensive Patients 72 Demonstrate Significant 72 R roscovitine CDK cyclin 72 CCX# B 72 Osteoporosis Drug 72 humanized interleukin 6 72 Glufosfamide 72 Million Milestone Payment 72 Demonstrates Sustained 72 Xcytrin R 72 Phase IIIb 72 Unfractionated Heparin 72 Pafuramidine 72 Paclitaxel Carboplatin 71 Tiotropium 71 Expanded Indication 71 Prostate Cancer Patients 71 Fungal Infections 71 Adjunctive Therapy 71 Kinase Inhibitor 71 PEGylated Fab fragment 71 Non Inferiority 71 randomized controlled Phase 71 LUX Lung 71 Initiates Clinical Trials 71 MKC# 71 SinuNase TM 71 Disease Progression 71 Taro Receives 71 Elderly Patients 71 Demonstrates Efficacy 71 Treated Patients 71 Tyrosine Kinase Inhibitor 71 Glatiramer Acetate 71 Combination Therapy 71 Systemic Delivery 71 Tipranavir 71 Capsules CII 71 Patient Enrolment 71 Sangamo BioSciences Announces 71 Intravitreal 71 Controlled Study 71 Shows Statistically Significant 71 Randomized Double Blind Placebo 71 Arthritis Drug 71 Omacetaxine 71 including eniluracil ADH 71 PDUFA Date 71 Bosutinib 71 Stent Restenosis 71 Tesetaxel 71 JAK2 Inhibitor 71 Presents Positive Preclinical 71 Placebo Controlled 71 Telaprevir VX 71 Novel Antibiotic 71 TLK# 71 TO AVOID PREGNANCY WHILE 71 Xeloda ® 71 CYT# potent vascular disrupting 71 TKB# 71 include Phenoptin TM 71 Patients Suffering 71 Pralatrexate 71 R lenalidomide 71 Cholesterol Lowering Drug 71 Vildagliptin 71 Acute Ischemic Stroke 71 Randomized Phase III 71 GOUT 71 sodium glucose cotransporter 71 Receives Orphan Drug 71 Diabetic Neuropathic Pain 71 FDA Clears 71 interferon gamma 1b 71 HCV Protease Inhibitor 71 AAG geldanamycin analog 71 Epilepsy Drug 71 Myelodysplastic Syndromes 71 Relapsing Remitting Multiple Sclerosis 71 Inhalation Solution 71 multicenter Phase 71 treatment naive genotype 71 Phase Ib Clinical Trial 71 Efficacy Results 71 Inhaled Corticosteroids 71 Myeloma Patients 71 First Patient Treated 71 FDA Okays 70 initiated Phase Ib 70 Immunomedics Announces 70 Adjuvant Therapy 70 Fixed Dose 70 Versus Placebo 70 virus HCV protease inhibitor 70 Antiviral Activity 70 Initiate Phase II 70 RNAi Therapeutic 70 Microplasmin 70 Oral Cladribine 70 Infected Patients 70 Naive Patients 70 Saxagliptin 70 Bazedoxifene 70 Cell Lymphoma 70 Interferon Beta 70 Platelet Inhibition 70 Sirolimus Eluting Stent 70 Drug Shows Promise 70 Transdermal Patch 70 Preclinical Study 70 Multicenter Phase 70 Cetrorelix 70 pralatrexate injection folate analogue 70 PRE SURGE 70 evaluating tivozanib 70 Randomized Study 70 Relapsed Refractory 70 albiglutide 70 Receives Fast Track 70 ACTEMRA TM 70 Postmenopausal Osteoporosis 70 evaluating picoplatin 70 Follicular Lymphoma 70 dasatinib Sprycel ® 70 Rigel R# 70 Prophylactic Treatment 70 Tesamorelin 70 Autologous Stem Cell Transplantation 70 Bipolar Depression 70 Receives Approvable Letter 70 registrational Phase 70 induced macular edema 70 MEK Inhibitor 70 Phase 2a Study 70 Placebo Controlled Trial 70 Rheumatoid Arthritis Patients 70 Pediatric Patients 70 orally administered inhibitor 70 Advaxis Phase 70 Hormone Receptor Positive 70 Reports Preclinical Data 70 Novel Inhibitor 70 Double Blind Randomized 70 Milestone Payment 70 Files Investigational 70 Receives Positive Opinion 70 Tolerability 70 Teva Provides Update 70 Low Dose 70 Golimumab 70 Malignant Glioma 70 Prostate AdenoCarcinoma Treatment 70 Rheumatoid Arthritis Drug 70 Chronic Hepatitis B 70 R#/MEM # 70 Janus kinase 70 Randomized Controlled 69 Preclinical Models 69 Advanced Colorectal Cancer 69 Migraine Drug 69 Schizophrenia Drug 69 Entereg R 69 Custirsen 69 Sirolimus Eluting 69 lintuzumab SGN 69 Archexin 69 Azacitidine 69 catheter occlusion 69 ORENCIA ® 69 Romidepsin 69 GALNS 69 Prostate Cancer Vaccine 69 includes TOLAMBA TM 69 Zoledronic Acid 69 VIVITROL ® 69 Oral Formulation 69 Perifosine KRX 69 Inhaled Insulin 69 Ecallantide 69 Chronic Sinusitis 69 Plaque Psoriasis 69 Cloretazine ® 69 APEX PD 69 Eluting Stent 69 Bortezomib 69 Sagent Pharmaceuticals Announces 69 Nilotinib 69 investigational monoclonal antibody 69 Synta Announces 69 JZP 69 phase IIb clinical 69 Systemic Sclerosis 69 Epratuzumab 69 Ceflatonin R 69 LymphoStat B belimumab 69 Romiplostim 69 Cholinesterase Inhibitors 69 Novel Mechanism 69 diarrhea predominant irritable 69 registrational trial 69 Sandostatin R 69 Cites Positive 69 Potent Antiviral Activity 69 Immunotherapeutic 69 Heart Failure Patients 69 Rotavirus Vaccine 69 Mg Uk 69 Treatment Experienced 69 IL# PE#QQR 69 approved incretin mimetic 69 Dapagliflozin 69 Overactive Bladder 69 Placebo Controlled Study 69 Pegylated Liposomal Doxorubicin 69 Randomized Trials 69 Stent Implantation 69 Elotuzumab 69 Adjuvant Chemotherapy 69 HGS ETR2 69 phase Ib 69 occlusion PAO 69 Vaccine Adjuvant 69 Telik logo TELINTRA 69 alfa 2a 69 Crofelemer budesonide foam 69 Pemetrexed 69 Receives Milestone Payment 69 Testosterone Gel 69 Panzem R 69 GATTEX TM 69 TRANSFORMS 69 Randomized Clinical Trials 69 Degarelix 69 Submits Biologics License Application 69 Cholesterol Drug 69 Colorectal Cancer Patients 69 acute peripheral arterial 69 Eszopiclone 69 Phase Ib II 69 cetuximab Erbitux R 69 Advanced Pancreatic Cancer 69 Bevacizumab 69 Voreloxin 69 Certolizumab 69 Diabetic Macular Edema 69 sorafenib tablets 69 fidaxomicin Phase 69 APPRAISE 69 comparing alemtuzumab 69 Ondansetron Injection USP 69 Completes Dosing 69 pan histone deacetylase 69 Luramist TM 69 selective A2A adenosine receptor 69 Erectile Dysfunction Drug 69 Oral Insulin 69 Diamyd Medical Diamyd 69 Monoclonal Antibody 69 Sustained Reduction 69 Cethromycin 69 Treatment Resistant 69 Ovitrelle R Serostim 69 Showed Significant 69 Announces Tentative Approval 69 See CLINICAL PHARMACOLOGY 69 CTAP# Capsules 69 2 methoxyestradiol 69 Pharmacokinetics PK 69 Valsartan 69 Histone Deacetylase 69 VEGFR2 inhibitor 69 Dasatinib 69 EOquin TM phase 69 Metabolic Efficiency 69 pan HDAC inhibitor 69 Phase #b/#a clinical 69 Testosterone MDTS R 69 complement inhibitor eculizumab 68 docetaxel Taxotere R 68 Civacir 68 MAGE A3 ASCI 68 assessing T DM1 68 Exelixis XL# 68 Patent Covering 68 Capecitabine 68 BRIM3 68 HER2 Positive Breast Cancer 68 Drug Eluting Stent System 68 Seliciclib CYC# 68 Nuvelo Announces 68 AN# topical anti 68 Genasense ® oblimersen 68 5 fluorouracil leucovorin 68 Carboplatin Paclitaxel 68 Improve Survival 68 Lubiprostone 68 Ophena TM 68 Receptor Agonist 68 oral ridaforolimus 68 Medullary Thyroid Cancer 68 Generic Versions 68 Allergic Rhinitis 68 TRANSDUR ™ 68 relapsed MM 68 Aliskiren 68 FDA APPROVES 68 ongoing Phase 1b 68 Receptor Antagonist 68 Methylnaltrexone 68 5 Fluorouracil 68 Clinical Study Shows 68 PROVENGE ® 68 inflammatory PDE 68 Camptosar ® 68 dextromethorphan quinidine 68 Fulvestrant 68 Tanespimycin 68 Kidney Transplant Patients 68 Hydrochlorothiazide Tablets 68 Significantly Improves 68 Slow Progression 68 Shows Promise Against 68 Diabetic Foot Ulcer 68 Chronic Myeloid Leukemia 68 Drug Combo 68 Seasonal Allergic Rhinitis 68 Neulasta ® 68 PEGINTRON TM 68 Brain Metastases 68 treatment naïve genotype 68 Breast Cancer Recurrence 68 Poniard Pharmaceuticals Announces 68 Novel Compound 68 agonistic human 68 IMPACT IMmunotherapy 68 Vascular Disrupting Agent 68 Anticancer Compound 68 Amrubicin 68 Hepatitis C Genotype 68 investigational humanized monoclonal antibody 68 multicenter Phase III 68 Bivalirudin 68 Multiple Ascending Dose 68 elotuzumab 68 Malignant Melanoma 68 Xelox 68 Gastrointestinal Stromal Tumors 68 MKC# MKC# PP 68 Polymerase Inhibitor 68 Irinotecan 68 Significantly Improved 68 Daclizumab 68 novel orally inhaled 68 Pirfenidone 68 Randomised 68 HuMax EGFr 68 phase IIb trial 68 Clolar ® 68 Hepatocellular Carcinoma 68 systemic Phase 1b 68 vapreotide acetate 68 Cardiovascular Outcomes 68 Treating Chronic 68 Supplemental Biologics License Application 68 fosbretabulin 68 INCB# [001] 68 Panzem R NCD 68 allosteric modulator NAM 68 topical gel formulation 68 Angiotensin Converting Enzyme 68 Vascular Inflammation 68 ACE Inhibitors 68 Extended Release 68 Matrix Phase 2b 68 Granulocyte Colony Stimulating Factor 68 Toremifene 68 Advanced Renal Cell 68 docetaxel Taxotere ® 68 sapropterin dihydrochloride Phase 68 RECORD1 68 liposomal formulation 68 unresectable stage 68 Neoadjuvant 68 Demonstrates Potential 68 Antitumor 68 INSPIRE Trial Phase III 68 Epidermal Growth Factor Receptor 68 Submits IND 68 Factor Receptor 68 Phase IIIb clinical 68 Previously Untreated 68 Primary Endpoint 68 Fewer Side Effects 68 ALN HPN 68 Secondary Hyperparathyroidism 68 Abiraterone Acetate 68 Significantly Reduced 68 PEGylated interferon beta 1a 68 Inhalation Aerosol 68 erlotinib Tarceva ® 68 Adalimumab 68 Lenocta TM 68 visilizumab 68 Vitrasert R 68 Gemzar ® 68 PEG IFN 68 Bare Metal Stents 68 Partial Onset Seizures 68 PEGylated anti 68 Pegloticase 68 FOLFOX6 chemotherapy regimen 68 Maribavir 68 Nebulized 68 Vandetanib 68 Chemotherapy Improves 68 Cannabinor 68 STELARA TM 68 AEG# 68 telomerase therapeutic 68 drug pipeline TAFA# 68 Clinical Trial Data 68 Zorbtive TM 68 Boceprevir 68 Linagliptin 68 phase IIb 68 Psoriasis Drug 68 Orphan Status 68 Phase IIa Trial 68 Proves Effective 68 retinal vein occlusion induced 68 Anticancer Agent 68 generation purine nucleoside 68 Fludarabine 68 Biogen Genentech 68 TNF Tumor Necrosis Factor 68 Ambrisentan 68 LibiGel ® 68 Acute Attacks 68 Hepatitis C Patients 68 ritonavir boosted 68 Contrave# 68 receptor tyrosine kinase inhibitor 68 Artery Disease 68 trastuzumab Herceptin R 67 Hematological Cancers 67 Reveals Positive 67 Mycophenolate Mofetil 67 PANVAC VF 67 Pramlintide 67 Interferon Alfa 67 R Saizen R 67 IIa Clinical Trial 67 RNAi Therapeutics 67 sunitinib Sutent ® 67 evaluating T DM1 67 generation antisense inhibitor 67 Esomeprazole 67 Alemtuzumab 67 brand ciclesonide HFA 67 Postmenopausal Women 67 methylnaltrexone bromide 67 Diabetic Neuropathy 67 Agonist MABA program 67 ara C 67 Myelodysplastic Syndrome MDS 67 Xyfid TM 67 CYP#A# CYP#D# 67 Natalizumab 67 Albuferon TM 67 relapsed refractory multiple myeloma 67 LEP ETU 67 Intervention Effectiveness 67 TELINTRA R 67 Prodrug 67 Immunosuppression 67 Clinical Outcome 67 ENDEAVOR IV 67 PHASE III 67 Appears Safe 67 Denufosol 67 Milestone Payment From 67 PSMA ADC 67 Inhaled Nitric Oxide 67 Disease Modifying 67 IMPACT DCM 67 Abciximab 67 azilsartan medoxomil 67 metastatic castration resistant 67 STRIDE PD 67 AVONEX ® 67 Pegylated Interferon 67 VIVUS Announces 67 Ocrelizumab 67 Phase IIb trials 67 erlotinib Tarceva R 67 Antibody Drug Conjugate 67 plus Copegus R 67 TELINTRA 67 metastatic castrate resistant 67 Calcium Acetate 67 Data Suggest 67 systemic juvenile idiopathic 67 Receives FDA Clearance 67 Clinical Efficacy 67 Castration Resistant Prostate Cancer 67 Augment TM 67 Alfimeprase 67 Enrolls First 67 Soft Tissue Sarcoma 67 sodium thiosulfate STS 67 Acute Myocardial Infarction 67 Treat Anemia 67 forodesine 67 Melphalan 67 beta 1a 67 Clinical Study 67 non nucleoside inhibitor 67 Zileuton 67 Significantly Reduces 67 Hemodialysis Patients 67 Announces Poster Presentations 67 chemotherapy FOLFOX 67 DU #b 67 Study Demonstrates 67 Universal Flu Vaccine 67 phase IIa clinical 67 STEALTH C 67 Tarceva TM 67 GVAX ® 67 Patient Outcomes 67 Clinical Trial 67 Unresectable 67 ORACLE MS 67 Humanized Anti 67 Decitabine 67 Myelofibrosis 67 Study Shows Promise 67 Cypher Sirolimus 67 Vidaza ® 67 atypical Hemolytic Uremic Syndrome 67 Paroxysmal Atrial Fibrillation 67 budesonide foam 67 refractory chronic lymphocytic 67 Iloperidone 67 Central Retinal Vein 67 Copegus ribavirin 67 Beta Blocker 67 antibody MAb 67 Atypical Hemolytic Uremic Syndrome 67 By JENNIFER LEARN 67 Gastric Cancer 67 PEG SN# 67 Percutaneous Tibial Nerve Stimulation 67 Intravenous Formulation 67 Hepatitis B Vaccine 67 blinded randomized placebo controlled 67 R# #mg BID 67 Recurrent Breast Cancer 67 Neovascular Age Related Macular 67 Therapy Evaluation 67 FEMALES SHOULD BE ADVISED 67 dasatinib Sprycel 67 Anthracycline 67 cutaneous T 67 Anticancer Drug 67 Predict Risk 67 Therapeutic Competitors Companies 67 Molecular Diagnostic Test 67 Multiple Myeloma Patients 67 Enrolling Patients 67 Anti Inflammatory Drug 67 Milestone Payments 67 Onyx Pharmaceuticals Announces 67 PKC# 67 Vaccine Candidate 67 PDX pralatrexate 67 orally inhaled migraine 67 Phenoptin 67 Mouse Model 67 Diabetic Patients 67 Metformin HCl 67 Initiates Dosing 67 PNP inhibitor 67 Interferon Gamma 67 Combination Clinical Trial 67 Fracture Risk 67 Preclinical Efficacy 67 Lung Cancer Survival 67 phase IIb III 67 Therapeutic Vaccine 67 Efficacious 67 6R BH4 67 HCV RESPOND 2 67 Delayed Release 67 Oral Mucositis 67 Xanafide 67 R#/MEM 67 Orally Active 67 Cancer Cachexia 67 Anti Clotting Drug 67 Knee Osteoarthritis 67 Lung Cancer Patients 67 R memantine HCl 67 Late Breaker 67 RELOVAIR ™ 67 Neoadjuvant Chemotherapy 67 Pharmacyclics Announces 67 selective phosphodiesterase 67 BENLYSTA TM 67 GVAX R 67 TAXUS ATLAS 67 Bepreve TM 67 CB2 selective receptor agonist 67 BR.# 67 Dual Opioid 67 colesevelam HCl 67 CIMZIA TM 67 familial amyloidotic polyneuropathy FAP 67 formerly LymphoStat B 67 CYP#A# substrate 67 Completes Patient Enrolment 67 Tumor Growth 67 Diffuse Large B 67 dose escalation clinical 67 Telithromycin 67 Phase IIB 67 AEGR 67 diarrhea fatigue asthenia 67 ALN PCS 67 Oral Insulin Capsule 67 Anemia Drug 67 Randomized Evaluation 67 Ofatumumab 67 BENLYSTA ™ 67 Patients Undergoing 67 Fondaparinux 67 KRN# 67 Bone Metastases 67 Phase Ib IIa 67 product candidate Lpathomab 67 Luveniq 67 Restenosis 67 alvespimycin 67 LymphoStat B TM 67 aripiprazole Abilify 67 metastatic hormone refractory 67 CD# CEA 67 Maleate 67 ABLYNX 67 Folfox 67 antibody MT# 67 Neulasta R 66 REG1 Anticoagulation System 66 selective modulator 66 Orally administered 66 Optimer Pharma 66 Fabry Disease 66 Anti CD# Antibody 66 Dose Response 66 Phospholipase A2 66 Infarct 66 omacetaxine mepesuccinate 66 Synthetic Peptide 66 Demonstrates Statistically Significant 66 metaglidasen 66 Nicotine Vaccine 66 MIVI III 66 Pimavanserin 66 icatibant 66 Phase Ib clinical 66 oral nucleoside analogue 66 Interferon beta 1a 66 HoFH 66 maximally tolerated dose 66 ChronVac C R 66 Pioglitazone 66 Varespladib 66 Ziprasidone 66 XL# anticancer compounds 66 Positive Opinion 66 mGluR5 NAM 66 Immunogenicity 66 EVIZON TM 66 Nymox NX 66 Tigecycline 66 FDA Approves 66 Tasimelteon 66 novel synthetic PEGylated 66 Clostridium difficile Infection 66 multicenter multinational 66 Replacement Therapy 66 L BLP# 66 mapatumumab 66 Telbivudine 66 BENCHMRK 66 Paliperidone Palmitate 66 Hepatic Encephalopathy 66 Carotid Stenting 66 refractory gout 66 Juvenile Idiopathic Arthritis 66 Bavituximab 66 Androgen Deprivation Therapy 66 myelodysplastic myeloproliferative diseases 66 ZOLINZA 66 Receptor Antagonists 66 Hematological Malignancies 66 ARRY # 66 Peginterferon alfa 2b 66 XYOTAX TM 66 ® decitabine 66 IMC #B 66 BENLYSTA ® 66 Cyclophosphamide 66 HCV Genotype 66 Beneficial Effects 66 Sustained Efficacy 66 Blind Placebo Controlled Trial 66 Oral Spray 66 Phase 1b 66 Phase Ib clinical trials 66 midstage clinical 66 terlipressin 66 EOquin TM 66 Tocilizumab 66 Bare Metal Stent 66 acyclovir Lauriad R 66 Bezielle 66 Alpha interferons including 66 Combo Therapy 66 HGS ETR1 mapatumumab 66 davunetide intranasal AL 66 Chronic Lymphocytic Leukemia CLL 66 QLT# 66 SUCCEED trial 66 Novel Anti Inflammatory 66 Acetate Rectal Suppositories 66 baminercept 66 evaluating bafetinib 66 Primary Hypercholesterolemia 66 Sipuleucel T 66 nab paclitaxel 66 EntreMed Presents 66 severe oral mucositis 66 ® lenalidomide 66 Chronic Heart Failure 66 Interferon Alpha 66 developing Bicifadine serotonin 66 EURIDIS 66 arsenic trioxide injection 66 FOLFOX6 66 AFREZZA TM 66 candidates Augment ™ 66 Aztreonam Lysine 66 Early Relapsing Multiple 66 recurrent metastatic ovarian cancer 66 BiovaxID TM 66 oncolytic virus therapies 66 Premenopausal Women 66 Diabetic Foot Ulcers 66 multicenter randomized Phase 66 Temsirolimus 66 Reduces Pain 66 Anticoagulant 66 compound INCB# 66 lucinactant 66 Sevelamer 66 Glucagon Like Peptide 66 Ovarian Cancer Patients 66 ST Elevation Myocardial 66 GENERIC SILDENAFIL SOFT Generic 66 Vitro Activity 66 prucalopride 66 investigational pan BCR 66 Cardiovascular Events 66 PROSTASCINT R 66 Prognostic Significance 66 5 HT3 antagonist 66 benzoic acid hyoscyamine sulfate 66 Vertebral Fracture 66 BRAF inhibitor 66 phase IIa 66 LAF# 66 Limb Ischemia 66 Naproxcinod 66 APF# Phase 66 Remission Maintenance 66 Syncria R 66 BARACLUDE R 66 cell lymphoma CTCL 66 Inflammatory Markers 66 RANK Ligand inhibitor 66 ALN VSP Phase 66 candidate XP# 66 oral proteasome inhibitor 66 evaluating satraplatin 66 BARACLUDE ® 66 NICE Recommends 66 primary hypercholesterolemia 66 lexidronam injection 66 investigational protease inhibitor 66 Interferon beta 1b 66 Therapeutic Antibody 66 vesicular monoamine transporter 66 Submits Response